DCZ0415|cas:2242470-43-3|西域试剂

DCZ0415,99.77%

产品编号：Bellancom-130603| CAS NO：2242470-43-3| 分子式：C₂₃H₂₀N₂O₂| 分子量：356.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-130603	￥1450.00	杭州北京（现货）
Bellancom-130603	￥2500.00	杭州北京（现货）
Bellancom-130603	￥5300.00	杭州北京（现货）
Bellancom-130603	￥9100.00	杭州北京（现货）
Bellancom-130603	￥0.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

DCZ0415

产品介绍

DCZ0415 是一种有效的 TRIP13 抑制剂，可损害非同源末端连接修复并抑制 NF-κB 活性。DCZ0415 在体外，体内以及在耐药性骨髓瘤患者衍生的原代细胞中诱导抗骨髓瘤活性。

生物活性

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients.

体外研究

DCZ0415 (10, 20 μM; 72 hours) shows a significant decrease in colony formation, indicating it inhibits cell proliferation.
DCZ0415 (1.25-40 μM; 72 hours) induces a significant dose-dependent decrease of viability in MM cells.
DCZ0415 (10, 20 μM; 24-72 hours) shows a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death.
DCZ0415 (10, 20 μM; 24 hours) induces a significant accumulation in G0/G1 MM cells.
DCZ0415 (10 μM; 48 hours) decreases the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells.
DCZ0415 has IC₅₀s of 1.0–10 μM in CalcuSyn in MM cell lines.
DCZ0415 exerts cytotoxic effects by inhibiting DNA 288 synthesis in MM cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	Multiple myeloma (MM) cells
Concentration:	10, 20 μM
Incubation Time:	72 hours
Result:	Showed a significant decrease in colony formation, indicating it inhibits cell proliferation.

Cell Viability Assay

Cell Line:	MM cells
Concentration:	1.25, 2.5, 5, 10, 20, 40 μM
Incubation Time:	72 hours
Result:	Induced a significant dose-dependent decrease of viability.

Apoptosis Analysis

Cell Line:	MM cells
Concentration:	10, 20 μM
Incubation Time:	24, 48, 72 hours
Result:	Showed a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death.

Cell Cycle Analysis

Cell Line:	MM cells
Concentration:	10 and 20 μM
Incubation Time:	24 hours
Result:	Induced a significant accumulation in G0/G1 MM cells.

Western Blot Analysis

Cell Line:	MM cells
Concentration:	10 μM
Incubation Time:	48 hours
Result:	Decreased the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells.

体内研究
(In Vivo)

DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (6-weeks-old) with H929 775 cells
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; every day for 14 days
Result:	Significantly reduced the growth of MM cells-induced tumors.

体内研究

DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (6-weeks-old) with H929 775 cells
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; every day for 14 days
Result:	Significantly reduced the growth of MM cells-induced tumors.

体内研究

DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (6-weeks-old) with H929 775 cells
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; every day for 14 days
Result:	Significantly reduced the growth of MM cells-induced tumors.

性状

Solid

溶解性数据

In Vitro:

DMSO : 62.5 mg/mL (175.35 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8057 mL	14.0284 mL	28.0568 mL
5 mM	0.5611 mL	2.8057 mL	5.6114 mL
10 mM	0.2806 mL	1.4028 mL	2.8057 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.84 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.84 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.84 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。